Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin to Present at September Investor Conferences
SAN DIEGO , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at two upcoming investor conferences in New York City , including: Cantor Fitzgerald Global Healthcare Conference Date: Monday, September 25,
View HTML
Toggle Summary Retrophin Announces Cooperative Research and Development Agreement with NCATS and NGLY1.org to Identify Potential Small Molecule Therapeutics for NGLY1 Deficiency
SAN DIEGO , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that it has entered into a three-way Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) and patient
View HTML
Toggle Summary Retrophin Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO , Aug. 14, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that its Compensation Committee granted inducement awards pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules on July 31, 2017 , August 7, 2017 and August 14, 2017 consisting of stock options to purchase
View HTML
Toggle Summary Retrophin Reports Second Quarter 2017 Financial Results
Fosmetpantotenate (RE-024) Phase 3 trial underway in PKAN Protocol design for pivotal Phase 3 trial of sparsentan in FSGS complete; sparsentan IP estate expanded to 2030 for FSGS Second quarter revenues increased 16 percent to $39 million SAN DIEGO , Aug.
View HTML
Toggle Summary Retrophin Chief Executive Officer Stephen Aselage Named to the 2017 PharmaVOICE 100
SAN DIEGO (August 1, 2017) – Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, has been named by PharmaVOICE magazine to the 2017 PharmaVOICE 100 – an award that recognizes the 100 Most Inspiring People in the life sciences industry. Mr.
View HTML
Toggle Summary Retrophin to Report Second Quarter 2017 Financial Results
SAN DIEGO , July 26, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report second quarter 2017 financial results on Wednesday, August 9, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin Commences Patient Dosing in International, Registrational Phase 3 Trial of RE-024 in PKAN
FORT Study to assess efficacy and safety of novel replacement therapy
View HTML
Toggle Summary Retrophin Announces Expansion of Intellectual Property Estate for Sparsentan with Newly Issued Patents in the United States and Europe
SAN DIEGO , June 01, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have each issued a patent covering the Company's product candidate sparsentan, which is advancing to Phase 3
View HTML
Toggle Summary Retrophin Announces Presentations for Late-Stage Clinical Development Programs at Upcoming Medical Congresses
Subgroup analysis from Phase 2 DUET study of sparsentan in FSGS to be presented at ERA-EDTA PKAN-ADL scale in Phase 3 FORT study of RE-024 in PKAN to be highlighted at MDS SAN DIEGO , May 25, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced upcoming presentations related to
View HTML
Toggle Summary Retrophin to Present at the Jefferies 2017 Global Healthcare Conference
SAN DIEGO , May 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the Jefferies 2017 Global Healthcare Conference in New York City on Tuesday, June 6, 2017 at 3:30 p.m. ET .
View HTML